Symplicity Makes Life Difficult For Renal Denervation Programs
This article was originally published in The Gray Sheet
Executive Summary
A big slice of the device industry, from large-cap firms to venture capitalists, is trying to understand the new reality in the wake of Medtronic’s announcement that its Symplicity hypertension trial missed its endpoint